Global U.S. Neuropathic Pain Treatment Market Overview:
Global U.S. Neuropathic Pain Treatment Market is expected to grow at a significant rate during the forecast period 2026-2035, with 2025 as the base year.
Global U.S. Neuropathic Pain Treatment Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of U.S. Neuropathic Pain Treatment involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the U.S. Neuropathic Pain Treatment Market:
The U.S. Neuropathic Pain Treatment Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for U.S. Neuropathic Pain Treatment Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study U.S. Neuropathic Pain Treatment Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, U.S. Neuropathic Pain Treatment market has been segmented into:
Pain Relievers (NSAIDS
Opioids (Tramadol
Oxycodone
and Others
By Application, U.S. Neuropathic Pain Treatment market has been segmented into:
Gabapentin
Pregabalin
and Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The U.S. Neuropathic Pain Treatment market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the U.S. Neuropathic Pain Treatment market.
Top Key Players Covered in U.S. Neuropathic Pain Treatment market are:
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
Johnson & Johnson
Dr. Reddy’s Laboratories Ltd.
Pfizer
Inc.
Cipla Inc.
Lupin Limited
Averitas Pharma
Inc.
NeuroBo Pharmaceuticals
Inc.
LEXICON PHARMACEUTICALS
INC.
Asahi Kasei Corporation
Vertex Pharmaceuticals Incorporated
Biogen
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: U.S. Neuropathic Pain Treatment Market by Type
4.1 U.S. Neuropathic Pain Treatment Market Snapshot and Growth Engine
4.2 U.S. Neuropathic Pain Treatment Market Overview
4.3 Pain Relievers (NSAIDS
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Pain Relievers (NSAIDS: Geographic Segmentation Analysis
4.4 Opioids (Tramadol
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Opioids (Tramadol: Geographic Segmentation Analysis
4.5 Oxycodone
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Oxycodone: Geographic Segmentation Analysis
4.6 and Others
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 and Others: Geographic Segmentation Analysis
Chapter 5: U.S. Neuropathic Pain Treatment Market by Application
5.1 U.S. Neuropathic Pain Treatment Market Snapshot and Growth Engine
5.2 U.S. Neuropathic Pain Treatment Market Overview
5.3 Gabapentin
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Gabapentin: Geographic Segmentation Analysis
5.4 Pregabalin
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Pregabalin: Geographic Segmentation Analysis
5.5 and Others
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 and Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 U.S. Neuropathic Pain Treatment Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 ELI LILLY AND COMPANY
6.4 JOHNSON & JOHNSON
6.5 DR. REDDY’S LABORATORIES LTD.
6.6 PFIZER
6.7 INC.
6.8 CIPLA INC.
6.9 LUPIN LIMITED
6.10 AVERITAS PHARMA
6.11 INC.
6.12 NEUROBO PHARMACEUTICALS
6.13 INC.
6.14 LEXICON PHARMACEUTICALS
6.15 INC.
6.16 ASAHI KASEI CORPORATION
6.17 VERTEX PHARMACEUTICALS INCORPORATED
6.18 AND BIOGEN
Chapter 7: Global U.S. Neuropathic Pain Treatment Market By Region
7.1 Overview
7.2. North America U.S. Neuropathic Pain Treatment Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Pain Relievers (NSAIDS
7.2.4.2 Opioids (Tramadol
7.2.4.3 Oxycodone
7.2.4.4 and Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Gabapentin
7.2.5.2 Pregabalin
7.2.5.3 and Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe U.S. Neuropathic Pain Treatment Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Pain Relievers (NSAIDS
7.3.4.2 Opioids (Tramadol
7.3.4.3 Oxycodone
7.3.4.4 and Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Gabapentin
7.3.5.2 Pregabalin
7.3.5.3 and Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe U.S. Neuropathic Pain Treatment Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Pain Relievers (NSAIDS
7.4.4.2 Opioids (Tramadol
7.4.4.3 Oxycodone
7.4.4.4 and Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Gabapentin
7.4.5.2 Pregabalin
7.4.5.3 and Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific U.S. Neuropathic Pain Treatment Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Pain Relievers (NSAIDS
7.5.4.2 Opioids (Tramadol
7.5.4.3 Oxycodone
7.5.4.4 and Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Gabapentin
7.5.5.2 Pregabalin
7.5.5.3 and Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa U.S. Neuropathic Pain Treatment Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Pain Relievers (NSAIDS
7.6.4.2 Opioids (Tramadol
7.6.4.3 Oxycodone
7.6.4.4 and Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Gabapentin
7.6.5.2 Pregabalin
7.6.5.3 and Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America U.S. Neuropathic Pain Treatment Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Pain Relievers (NSAIDS
7.7.4.2 Opioids (Tramadol
7.7.4.3 Oxycodone
7.7.4.4 and Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Gabapentin
7.7.5.2 Pregabalin
7.7.5.3 and Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
U.S. Neuropathic Pain Treatment Scope:
|
Report Data
|
U.S. Neuropathic Pain Treatment Market
|
|
U.S. Neuropathic Pain Treatment Market Size in 2025
|
USD XX million
|
|
U.S. Neuropathic Pain Treatment CAGR 2025 - 2032
|
XX%
|
|
U.S. Neuropathic Pain Treatment Base Year
|
2024
|
|
U.S. Neuropathic Pain Treatment Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., NeuroBo Pharmaceuticals, Inc., LEXICON PHARMACEUTICALS, INC., Asahi Kasei Corporation, Vertex Pharmaceuticals Incorporated, and Biogen.
|
|
Key Segments
|
By Type
Pain Relievers (NSAIDS
Opioids (Tramadol
Oxycodone
and Others
By Applications
Gabapentin
Pregabalin
and Others
|
